Insmed Incorporated (NASDAQ:INSM – Get Free Report) insider Michael Alexander Smith sold 27,871 shares of Insmed stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $74.35, for a total value of $2,072,208.85. Following the completion of the sale, the insider now owns 67,856 shares of the company’s stock, valued at $5,045,093.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Insmed Stock Performance
Insmed stock opened at $73.26 on Wednesday. The stock’s 50 day moving average price is $74.78 and its 200 day moving average price is $51.24. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. The firm has a market capitalization of $10.89 billion, a PE ratio of -14.01 and a beta of 1.11. Insmed Incorporated has a one year low of $21.92 and a one year high of $80.53.
Insmed (NASDAQ:INSM – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.72). The business had revenue of $90.34 million for the quarter, compared to analysts’ expectations of $87.95 million. Insmed’s revenue for the quarter was up 17.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.78) earnings per share. As a group, sell-side analysts expect that Insmed Incorporated will post -5.42 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Several brokerages have recently commented on INSM. TD Cowen increased their price objective on Insmed from $75.00 to $98.00 and gave the company a “buy” rating in a report on Friday, August 9th. Morgan Stanley lifted their target price on shares of Insmed from $60.00 to $85.00 and gave the company an “overweight” rating in a report on Friday, July 12th. Mizuho raised their price objective on Insmed from $36.00 to $82.00 and gave the company a “buy” rating in a report on Friday, June 7th. Wells Fargo & Company upped their price target on shares of Insmed from $55.00 to $77.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 29th. Finally, UBS Group lifted their target price on shares of Insmed from $78.00 to $84.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, Insmed currently has an average rating of “Moderate Buy” and a consensus target price of $79.19.
Check Out Our Latest Research Report on Insmed
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Featured Stories
- Five stocks we like better than Insmed
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Stock Market Sectors: What Are They and How Many Are There?
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- What Is WallStreetBets and What Stocks Are They Targeting?
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.